Dec 30 (Reuters) - Actinogen Medical Ltd ACW.AX
* requests that its securities be placed into an immediate trading halt pending an announcement regarding actinogen medical's application to FDA
* application to fda to initiate its Xanadu phase ii clinical trial in us of xanamem in treatment of Alzheimer's disease. Source text for Eikon: ID:nASX44Z32w Further company coverage: ACW.AX